$STVN

MOREL DONALD E JR sold $26K of STVN

MOREL DONALD E JR sold 1,493 shares of Stevanato Group S.p.A. (STVN) at $17.09 on 2026-06-15.

Original reporting
SEC EDGAR · MOREL DONALD E JR
Published Jun 26, 2026, 10:12 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 26, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STVN
Neutral
high confidence
Mentioned
$STVN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value, and post-transaction holdings). This can marginally influence sentiment but does not change the company’s fundamentals based on the provided text.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no new guidance, deal, or operational datapoint here.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide context on total compensation or prior holdings beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-06-26 (sale dated 2026-06-15)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Stevanato Group S.p.A.

Company-level read

Ticker impact

$STVNNeutralHigh confidence
Context

Stevanato Group director MOREL DONALD E JR filed a Form 4 open-market sale of 1,493 shares at $17.09 on 2026-06-15.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any impact is likely short-lived.

Evidence & confidence

The filing is a small, disclosed open-market sale with no 10b5-1 plan and no accompanying fundamental news in the text.

Market effects

No sector-level implications; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax- or diversification-driven and may not reflect bearish fundamentals, especially when the transaction is disclosed as open-market.

Key entities

  • Stevanato Group S.p.A.

    Subject of the Form 4 insider transaction disclosure (STVN).

  • MOREL DONALD E JR

    Director who sold 1,493 shares in an open-market sale; filing reported via SEC EDGAR.

Related articles

$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.

$STVNMed

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.

$STVNMedAI 8/10

Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.